Celecoxib and heterotopic bone formation after total hip arthroplasty

Journal of Arthroplasty

Volumn 29, Issue 2, 2014, Pages 390-392

  Lavernia, Carlos J ^a   Contreras, Juan S ^b   Villa, Jesus M ^b   Rossi, Mark D ^c  

^a Mercy Hospital Miami   (United States)

^b Arthritis Surgery Research Foundation   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Celecoxib; Heterotopic ossification; Prevention; Primary hip arthroplasty; Total hip replacement

Indexed keywords

CELECOXIB;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HETEROTOPIC OSSIFICATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAIN; PROSTHESIS LOOSENING; TOTAL HIP PROSTHESIS; VERY ELDERLY; YOUNG ADULT;

CELECOXIB; HETEROTOPIC OSSIFICATION; PREVENTION; PRIMARY HIP ARTHROPLASTY; TOTAL HIP REPLACEMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT, HIP; HIP JOINT; HUMANS; JOINT DISEASES; MIDDLE AGED; OSSIFICATION, HETEROTOPIC; PYRAZOLES; RETROSPECTIVE STUDIES; SULFONAMIDES; YOUNG ADULT;

EID: 84892496507     PISSN: 08835403     EISSN: 15328406     Source Type: Journal    
DOI: 10.1016/j.arth.2013.06.039     Document Type: Article

References (33)

1. Brooker A.F., Bowerman J.W., Robinson R.A., et al. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am 1973, 55(8):1629.
2. Purtill J.J., Eng K., Rothman R.H., et al. Heterotopic ossification. Incidence in cemented versus cementless total hip arthroplasty. J Arthroplasty 1996, 11(1):58.
3. Ritter M.A., Vaughan R.B. Ectopic ossification after total hip arthroplasty. Predisposing factors, frequency, and effect on results. J Bone Joint Surg Am 1977, 59(3):345.
4. Della Valle A.G., Ruzo P.S., Pavone V., et al. Heterotopic ossification after total hip arthroplasty: a critical analysis of the Brooker classification and proposal of a simplified rating system. J Arthroplasty 2002, 17(7):870.
5. Pape H.C., Marsh S., Morley J.R., et al. Current concepts in the development of heterotopic ossification. J Bone Joint Surg Br 2004, 86(6):783.
6. Ahrengart L. Periarticular heterotopic ossification after total hip arthroplasty. Risk factors and consequences. Clin Orthop Relat Res 1991, (263):49.
7. Pagnani M.J., Pellicci P.M., Salvati E.A. Effect of aspirin on heterotopic ossification after total hip arthroplasty in men who have osteoarthrosis. J Bone Joint Surg Am 1991, 73(6):924.
8. Ahrengart L., Lindgren U. Functional significance of heterotopic bone formation after total hip arthroplasty. J Arthroplasty 1989, 4(2):125.
9. DeLee J., Ferrari A., Charnley J. Ectopic bone formation following low friction arthroplasty of the hip. Clin Orthop Relat Res 1976, (121):53.
10. Pellegrini V.D., Konski A.A., Gastel J.A., et al. Prevention of heterotopic ossification with irradiation after total hip arthroplasty. Radiation therapy with a single dose of eight hundred centigray administered to a limited field. J Bone Joint Surg Am 1992, 74(2):186.
11. Amstutz H.C., Fowble V.A., Schmalzried T.P., et al. Short-course indomethacin prevents heterotopic ossification in a high-risk population following total hip arthroplasty. J Arthroplasty 1997, 12(2):126.
12. Knelles D., Barthel T., Karrer A., et al. Prevention of heterotopic ossification after total hip replacement. A prospective, randomised study using acetylsalicylic acid, indomethacin and fractional or single-dose irradiation. J Bone Joint Surg Br 1997, 79(4):596.
13. McMahon J.S., Waddell J.P., Morton J. Effect of short-course indomethacin on heterotopic bone formation after uncemented total hip arthroplasty. J Arthroplasty 1991, 6(3):259.
14. Leese P.T., Hubbard R.C., Karim A., et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000, 40(2):124.
15. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000, 284(10):1247.
16. Romano C.L., Duci D., Romano D., et al. Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. J Arthroplasty 2004, 19(1):14.
17. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352(11):1092.
18. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365(9458):475.
19. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343(21):1520.
20. Mamdani M., Juurlink D.N., Lee D.S., et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004, 363(9423):1751.
21. Ray W.A., Stein C.M., Daugherty J.R., et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 360(9339):1071.
22. Solomon D.H., Schneeweiss S., Glynn R.J., et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004, 109(17):2068.
23. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352(11):1071.
24. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355(9):873.
25. Solomon S.D., Wittes J., Finn P.V., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008, 117(16):2104.
26. Barthel T., Baumann B., Noth U., et al. Prophylaxis of heterotopic ossification after total hip arthroplasty: a prospective randomized study comparing indomethacin and meloxicam. Acta Orthop Scand 2002, 73(6):611.
27. Grohs J.G., Schmidt M., Wanivenhaus A. Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up. Acta Orthop 2007, 78(1):95.
28. van der Heide H.J., Koorevaar R.C., Lemmens J.A., et al. Rofecoxib inhibits heterotopic ossification after total hip arthroplasty. Arch Orthop Trauma Surg 2007, 127(7):557.
29. van der Heide H.J., Rijnberg W.J., Van Sorge A., et al. Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty. Acta Orthop 2007, 78(1):90.
30. Saudan M., Saudan P., Perneger T., et al. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial. J Bone Joint Surg Br 2007, 89(2):155.
31. Ahrengart L., Lindgren U. Heterotopic bone after hip arthroplasty. Defining the patient at risk. Clin Orthop Relat Res 1993, (293):153.
32. Eggli S., Woo A. Risk factors for heterotopic ossification in total hip arthroplasty. Arch Orthop Trauma Surg 2001, 121(9):531.
33. Higo T., Mawatari M., Shigematsu M., et al. The incidence of heterotopic ossification after cementless total hip arthroplasty. J Arthroplasty 2006, 21(6):852.